Han Wang,Susan J Kim,Yu Lei et al.
Han Wang et al.
Neutrophil extracellular traps (NETs), crucial in immune defense mechanisms, are renowned for their propensity to expel decondensed chromatin embedded with inflammatory proteins. Our comprehension of NETs in pathogen clearance, immune regul...
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial [0.03%]
注射用伊立替康脂质体制剂HR070803联合氟尿嘧啶和亚叶酸钙治疗既往吉西他滨为基础的方案治疗失败的局部晚期或转移性胰腺导管腺癌患者：一项III期临床试验
Jiujie Cui,Shukui Qin,Yuhong Zhou et al.
Jiujie Cui et al.
Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-contro...
The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma [0.03%]
p-MYH9/USP22/HIF-1α轴通过促进肝细胞癌的仑伐替尼抗性和癌症干细胞样特性发挥促肿瘤作用
Qiaonan Shan,Lu Yin,Qifan Zhan et al.
Qiaonan Shan et al.
Lenvatinib is a targeted drug used for first-line treatment of hepatocellular carcinoma (HCC). A deeper insight into the resistance mechanism of HCC against lenvatinib is urgently needed. In this study, we aimed to dissect the underlying me...
Characterization of ACTN4 as a novel antiviral target against SARS-CoV-2 [0.03%]
表征ACTN4作为针对SARS-CoV-2的新型抗病毒靶点
Miao Zhu,Fang Huang,Huize Sun et al.
Miao Zhu et al.
The various mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose a substantial challenge in mitigating the viral infectivity. The identification of novel host factors influencing SARS-CoV-2 replication holds potent...
Zhikai Zheng,Yao Zong,Yiyang Ma et al.
Zhikai Zheng et al.
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifical...
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial [0.03%]
斯鲁利单抗联合安罗替尼和化疗用于广泛期小细胞肺癌二线及以上治疗的II期临床试验
Xiao Han,Jun Guo,Lingyu Li et al.
Xiao Han et al.
Treatment options for patients with relapsed extensive-stage small cell lung cancer (ES-SCLC) remain scarce. This study aims to evaluate the efficacy and safety of combining anlotinib and sintilimab plus chemotherapy as a second line or lat...
Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases [0.03%]
表观遗传新视野：组蛋白修饰与疾病的新联系
Weiyi Yao,Xinting Hu,Xin Wang
Weiyi Yao
Histone post-translational modifications (HPTMs), as one of the core mechanisms of epigenetic regulation, are garnering increasing attention due to their close association with the onset and progression of diseases and their potential as ta...
Type 2 diabetes across populations of different ancestry: deconstructing the genomic landscape [0.03%]
不同祖先人群中2型糖尿病的遗传结构差异：解读基因组景观
Georgia Xourafa,Christian Herder,Michael Roden
Georgia Xourafa
Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges [0.03%]
转化挑战中的间充质干细胞的药代动力学特征
Yunlong Shan,Mengying Zhang,Enxiang Tao et al.
Yunlong Shan et al.
Over the past two decades, mesenchymal stem/stromal cell (MSC) therapy has made substantial strides, transitioning from experimental clinical applications to commercial products. MSC therapies hold considerable promise for treating refracto...
One step at a time: new insights into double-stranded ribonucleic acid virus assembly [0.03%]
一步一个脚印：双链RNA病毒装配新见解
Virgile Rat,Alexander Borodavka,Don C Lamb
Virgile Rat